Avandia Linked To Over 300 Deaths In 3rd Quarter Of 2009
GlaxoSmithKline's (GSK) Type 2 diabetes drug, Avandia, has been linked to over 300 deaths in the third quarter of 2009 alone according to secret government documents obtained by the New York Times. This staggering number has prompted the U.S. Food & Drug Administration (FDA) to reassess the drug's future in meetings this summer.
Avandia injuries / Avandia deaths
Avandia plaintiffs' lawyers say that hundreds, if not thousands, of injuries and deaths have been linked to GSK's Avandia (rosiglitazone) – and the latest allegations are simply unbelievable. According to confidential government information recently obtained and published by the New York Times:
[I]f every diabetic now taking Avandia were instead given a similar pill named Actos, about 500 heart attacks and 300 cases of heart failure would be averted every month...
Equate those numbers to an annual basis and you've got staggering results. The Times reported that Dr. Kate Gelperin and Dr. David Graham, both of the FDA, concluded that Avandia should be removed from the market. Their conclusions, along with the other information recently published, has caused the FDA to take yet another look at whether Avandia should continue to be sold. It will do so this summer after convening an advisory panel.
Allegations of foul play
Many Avandia users who have been injured, and families of those who have died, after using the drug have accused GSK of foul play in order to increase the company's bottom line. In particular, the company may have fraudulently withholding information on the safety and effectiveness of its drug. GSK settled those allegations for $2.5 million with the New York Attorney General in 2007. Even the FDA has accused GSK of withholding studies – nine different studies to be exact – after it inspected the company's offices in North Carolina.
More damaging information about Avandia
Damaging information about Avandia is plentiful. The drug is already subject to FDA black box warnings and numerous medical journals and research facilities, such as The New England Journal of Medicine, The British Medical Journal, The American Journal of Ophthalmology, The Institute for Clinical Evaluative Science, Wake University School of Medicine and The University of East Anglia in England have said that Avandia may increase the risk of:
- heart attack
- heart failure
- bone fracture
- liver toxicity
- severe vision problems such as diabetic macular edema, or DME.
Product liability lawyers say that the latest information on Avandia published by the Times may just force GSK to pull the drug off the market. However, they say that even if that happens, anyone injured by Avandia can still bring a personal injury lawsuit against the pharmaceutical giant. An experienced Avandia injury attorney can evaluate your situation in confidence and without obligation.